Intravenous Delivery of Targeted Liposomes to Amyloid-β Pathology in APP/PSEN1 Transgenic Mice

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Tanifum, Eric A ^a,b   Dasgupta, Indrani ^b,f   Srivastava, Mayank ^a,b   Bhavane, Rohan C ^a,b   Sun, Li ^c   Berridge, John ^c   Pourgarzham, Hoda ^c   Kamath, Rashmi ^a   Espinosa, Gabriela ^a   Cook, Stephen C ^e   Eriksen, Jason L ^b   Annapragada, Ananth ^a,b,d  

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF HOUSTON   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e Fieldstone Partners   (United States)

^f UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 DISTEAROYL SN GLYCERO 3 PHOSPHOETHANOLAMINE N[METHOXY XO4 (POLYTHYLENE GLYCOL 3400)]SODIUM SALT; AMYLOID BETA PROTEIN; FLUORESCENT DYE; LIPOSOME; NANOPARTICLE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING COMPETITION; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG BINDING; DRUG DISTRIBUTION; DRUG LABELING; DRUG STRUCTURE; DRUG SYNTHESIS; IMMUNOFLUORESCENCE TEST; IN VITRO STUDY; MOUSE; NONHUMAN; PROTEIN LOCALIZATION; TRANSGENIC MOUSE;

ADMINISTRATION, INTRAVENOUS; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BLOOD-BRAIN BARRIER; CEREBRAL CORTEX; DISEASE MODELS, ANIMAL; HIPPOCAMPUS; LIPOSOMES; MICE; MICE, TRANSGENIC; PHOSPHATIDYLETHANOLAMINES; PLAQUE, AMYLOID; POLYETHYLENE GLYCOLS; PRESENILIN-1; PROTEIN BINDING;

MUS MUSCULUS;

EID: 84868319492     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0048515     Document Type: Article

References (56)

1. Alzheimer's Association, (2012) Alzheimer's Association Report: 2012 Alzheimer's Disease Facts and Figures, Alzheimer's & Dementia. 8: 131-168.
2. Alzheimer's Disease International (2010) World Alzheimer Report 2009: The Global Economic Impact of Dementia. Available: http://www.alz.co.uk/research/files/World Alzheimer Report 2010.pdf. Accessed 2011 Aug 01.
3. Folstein MF, Folstein SE, McHugh PR, (1975) "Mini-Mental State". A Practical Method for Grading the Cognitive State of Patients for the Clinician. J Psychiatr Res 12: 189-98.
4. Braak H, Braak E, (1997) Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories. Neurobiol Aging 18: 351-357.
5. Thal DR, Rub U, Orantoes M, Braak H, (2002) Phases of A-beta Deposition in the Human Brain and its Relevance for the Development of AD. Neurology 58: 1791-1800.
6. Tarawneh R, Holtzman DM, (2010) Biomarkers in Translational Research of Alzheimer's Disease. Neuropharmacology 59: 310-322.
7. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, et al. (2011) Toward Defining the Preclinical Stages of Alzheimer's Disease: Recommendations from the National Institute on Aging-Alzheimer's Association Workgroups on Diagnostic Guidelines for Alzheimer's Disease. Alzheimer's & Dementia 7: 280-292.
8. Lucignani G, (2009) Amyloid Imaging with PET: Methodological Issues and Correlative Studies. Eur J Nucl Med Mol Imaging 36: 1009-1014.
9. Choi SR, Golding G, Zhuang Z, Zhang W, Lim N, et al. (2009) Preclinical Properties of 18F-AV-45: a PET Agent for Aβ Plaques in the Brain. The Journal of Nuclear Medicine 50: 1887-1894.
10. Wang J, Maurer L, (2005) Positron Emission Tomography: Applications in Drug Discovery and Drug Development. Curr Top Med Chem 5: 1053-1075.
11. Armstrong RA, (1999) Do β-Amyloid (Aβ) Deposits in Patients with Alzheimer's Disease and Down's Syndrome Grow According to the Log-Normal Model? Neurosci Lett 261: 97-100.
12. Bussière T, Bard F, Barbour R, Grajeda H, Guido T, et al. (2004) Morphological Characterization of Thioflavin-S-Positive Amyloid Plaques in Transgenic Mice and Effect of Aβ Immunotherapy on their Clearance. Am J Pathol 165: 987-995.
13. Fiala JC, (2007) Mechanism of Amyloid Plaque Pathogenesis. Acta Neuropathol 114: 551-571.
14. Drzezga A, (2008) Basic Pathologies of Neurodegenerative Dementias and Their Relevance for State-of-the-Art Molecular Imaging. Eur J Med Mol Imaging 35: S4-S11.
15. Pike KE, Savage G, Villemagne VL, Ng S, Moss SA, et al. (2007) β-Amyloid Imaging and Memory in Non-Demented Individuals: Evidence for Preclinical Alzheimer's Disease. Brain 130: 2837-2844.
16. Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, et al. (2008) Frequent Amyloid Deposition Without Significant Cognitive Impairment Among the Elderly. Arch Neurol 65: 1509-1517.
17. Reiman EM, Chen K, Liu X, Bandy D, Yu M, et al. (2009) Fibrillar Amyloid-Beta Burden in Cognitively Normal People at 3 Levels of Genetic Risk for Alzheimer Disease. Proc Natl Acad Sci USA 106: 6820-6825.
18. Iadecola C, (2004) Neurovascular Regulation in the Normal Brain and in Alzheimer's Disease. Nat Rev Neurosci 5: 347-360.
19. Zlokovic BV, (2005) Neurovascular Mechanisms of Alzheimer's Neurodegeneration. Trends Neurosci 28: 202-208.
20. Benarroch E, (2007) Neurovascular Unit Dysfunction: a Vascular Component of Alzheimer's Disease. Neurology 68: 1730-1732.
21. Zipser BD, Johanson CE, Gonzales L, Berzin TM, Tavares R, et al. (2007) Microvascular Injury and Blood-Brain Barrier Leakage in Alzheimer's Disease. Neurobiol Aging 28: 977-986.
22. Kumar-Singh S, Pirici D, McGowan E, Serneels S, Ceuterick C, et al. (2005) Dense-Core Plaques in Tg2576 and PSAPP Mouse Models of Alzheimer's Disease are Centered on Vessel Walls. Am J Pathol 167: 527-543.
23. Meyer EP, Ulmann-Sculer A, Staufenbiel M, Krucker T, (2008) Altered Morphology and 3D Architecture of Brain Vasculature in a Mouse Model of Alzheimer's Disease. Proc Natl Acad Sci U. S. A 105: 3587-3592.
24. Paris D, Humphrey J, Quadros A, Patel N, Crescentini R, et al. (2003) Vasoactive Effects of Aβ in Isolated Human Cerebrovessels and in a Transgenic Mouse Model of Alzheimer's Disease: Role of Inflammation. Neurol Res 25: 642-651.
25. Cullen KM, Kocsi Z, Stone J, (2006) Microvascular Pathology in the Aging Human Brain: Evidence that Senile Plaques are Sites of Microhaemorrhages. Neurobiol. Aging 27: 1786-1796.
26. Biron KE, Dickstein DL, Gopaul R, Jefferies WA, (2011) Amyloid Triggers Extensive Cerebral Angiogenesis Causing Blood Brain Barrier Permeability and Hypervascularity in Alzheimer's Disease. PloS ONE 6(8): e23789.
27. Maeda H, (1991) SMANCS and Polymer-Conjugated Macromolecar Drugs: Advantages in Cancer Chemotherapy. Adv Drug Delivery Rev 6: 181-202.
28. Weller RO, Subash M, Preston SD, Mazanti I, Carare RO, (2008) Perivascular Drainage of Amyloid-Beta Peptides from the Brain and its Failure in Cerebral Amyloid Angiopathy and Alzheimer's Disease. Brain Pathol 18: 253-266.
29. Carare RO, Bernardes-Silva M, Newman TA, Page AM, Nicoll JA, (2008) Solutes, but not Cells, Drain from the Brain Parenchyma Along Basement Membranes of Capillaries and Arteries. Significance for Cerebral Amyloid Angiopathy and Neuroimmunology. Neuropathol Appl Neurobiol 34: 131-144.
30. Ball KK, Cruz NF, Mrak RE, Dienel GA, (2010) Trafficking of Glucose, Lactate, and Amyloid-β from the Inferior Colliculus Through Perivascular Routes. J Cereb Blood Flow Metab 30: 162-176.
31. Abbott NJ, (2004) Evidence for Bulk Flow of Brain Interstitial Fluid: Significance for Physiology and Pathology. Neurochem Int 45: 545-552.
32. Weller RO, Djuanda E, Yow H-Y, Carare RO, (2009) Lymphatic Drainage of the Brain and the Pathophysiology of Neurological Disease. Acta Neuropathol 117: 1-14.
33. Herzig MC, Van Nostrand WE, Jucker M, (2006) Mechanism of Cerebral Beta-Amyloid Angiopathy: Murine and Cellular Models. Brain Pathol 16: 40-54.
34. Weller RO, Massey A, Newman TA, Hutchings M, Kuo YM, et al. (1998) Cerebral Amyloid Angiopathy: Amyloid Beta Accumulates in Putative Interstitial Fluid Drainage Pathways in Alzheimer's Disease. Am J Pathol 153: 725-733.
35. Nicoll JAR, Yamada M, Frackowiak J, Mazur-Kolecka B, Weller RO, (2004) Cerebral Amyloid Angiopathy Plays a Direct Role in the Pathogenesis of Alzheimer's Disease. Pro-CAA Position Statement. Neurobiol Aging 25: 589-597.
36. Mukundan S Jr, Ghaghada KB, Badea CT, Kao CY, Hedlund LW, et al. (2006) A Liposomal Nanoscale Contrast Agent for Preclinical CT in Mice. ARJ Am J Roentgenol 186: 300-307.
37. Ghaghada KB, Ravoori M, Sabapathy D, Bankson J, Kundra V, et al. (2009) New Dual Mode Gadolinium Nanoparticle Contrast Agent for Magnetic Resonance Imaging. PloS ONE 4(10): e7628.
38. Klunk WE, Bacskai BJ, Mathis CA, Kajdasz ST, McLellan ME, et al. (2002) Imaging Aβ Plaques in Living Transgenic Mice with Multiphotonmicrospray and Methoxy-X04, a Systemic Administered Congo Red Derivative. J Neuropathol Exp Neurol 61: 797-805.
39. Takai K, Nitta K, Utimoto K, (1986) Simple and Selective Method for Aldehydes (RCHO)-> (E)-Haloalkenes (RCH = CHX) Conversion by Means of a Haloform-Chromous Chloride System. J Am Chem Soc 108: 7408-7410.
40. Miyaura N, Suzuki A (1979) Stereoselective Synthesis of Arylated (E)-Alkenes by the Reaction of Alka-1-Enylboranes with Arylhalides in the Presence of Palladium Catalyst. J Chem Soc Chem Commun: 866-867.
41. Blakemore PR, Cole WJ, Kocienski PJ, Morley AA (1998) Stereoselective Synthesis of Trans-1,2-Sisubstituted Alkenes Based on the Condensation of Aldehydes with Metallated 1-Phenyl-1H-Tetrazol-5-yl Sulfones. Synlett: 26-28.
42. Lockhart A, (2006) Imaging Alzheimer's Disease Pathology: One Target Many Ligands. Drug Discovery Today 11: 1093-1099.
43. Mathis CA, Wang Y, Klunk WE, (2004) Imaging β-Amyloid Plaques and Neurofibrillary Tangles in the Aging Human Brain. Curr Pharm Des 10: 1469-1492.
44. Lochart A, Ye L, Judd DB, Merritt AT, Lowe PN, et al. (2005) Evidence for the Presence of Three Distinct Binding Sites for the Thioflavin T Class of Alzheimer's Disease PET Imaging Agents on Beta-Amyloid Peptite Fibrils. J Biol Chem 280: 7677-7684.
45. Zhang W, Oya S, Kung M-P, Hou C, Maier DL, et al. (2005) F-18 Stilbenes as PET Imaging Agents for Detecting β-Amyloid Plaques in the Brain. J Med Chem 48: 5980-5988.
46. Amatsubo T, Morikawa S, Inubushi T, Urushitani M, Taguchi H, et al. (2009) Trifluoromethoxy-Benzylated Ligands Improve Amyloid Detection in the Brain Using 19F Magnetic Resonance Imaging. Neurosci Res 63: 76-81.
47. Bell RD, Zlokovic BV, (2009) Neurovascular Mechanisms and Blood-Brain Barrier Disorder in Alzheimer's Disease. Acta Neuropathol 118: 103-113.
48. Bell RD, Sagare AP, Friedman AE, Bedi GS, Holtzman DM, et al. (2007) Transport Pathways for Clearance of Human Alzheimer's Amyloid β-Peptide and Apolipoproteins E and J in the Mouse Central Nervous System. J Cereb Blood Flow Metab 27: 909-918.
49. Torchilin VP, (2005) Recent Advances with Liposomes as Pharmaceutical Carriers. Nat Rev Drug Discovery 4: 145-160.
50. Gobbi M, Francesca Re F, Canovi M, Beeg M, Gregori M, et al. (2010) Lipid-Based Nanoparticles with High Binding Affinity for Amyloid-β1-42 Peptide. Biomaterials 31: 6519-6529.
51. Mourtas S, Canovi M, Zona C, Aurilia D, Niarakis A, et al. (2011) Curcumin-Decorated Nanoliposomes with Very High Affinity for Amyloid-β1-42 Peptide. Biomaterials 32: 1635-1645.
52. Hatanaka Y, Hashimoto M, Kanaoka Y, (1994) A Novel Biottinylated Heterobifunctional Cross-linking Reagent Bearing an Aromatic Diazirine. Bioorg Med Chem 2 (12): 1367-1373.
53. Schlapbach A, Feifel R, Hawtin S, Heng R, Koch G, et al. (2008) Pyrrolo-pyrimidones: a Novel Class of MK2 Inhibitors with Potent Cellular Activity. Bioorg Med Chem Lett 18(23): 6142-6.
54. Borchelt DR, Ratovitski T, van Lare J, Lee MK, Gonzales V, et al. (1997) Accelerated Amyloid Deposition in the Brains of Transgenic Mice Coexpressing Mutant Presenilin 1 and Amyloid Precursor Proteins. Neuron 19: 939-945.
55. Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, et al. (1998) Accelerated Alzheimer-Type Phenotype in Transgenic Mice Carrying both Mutant Amyloid Precursor Protein and Presenilin 1 Transgenes. Nat Med 4: 97-100.
56. Jankowsky JL, Slunt HH, Ratovitski T, Jenkins NA, Copeland NG, et al. (2001) Co-expression of Multiple Transgenes in Mouse CNS: A Comparison of Strategies. Biomol Eng 17: 157-165.